Embracing model-based designs for dose-finding trials

Sharon B Love, Sarah Brown, Christopher Weir, Chris Harbron, Christina Yap, Birgit Gaschler-Markefski, James Matcham, Victoria Cornelius

Research output: Contribution to conferencePosterpeer-review

Abstract

Background
Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose-finding, such as the continual reassessment method (CRM).
Method
We carried out a literature review of dose-finding designs and conducted a survey to identify perceived barriers to their implementation.
Results
We describe the benefits of model-based designs (flexibility, superior operating characteristics, extended scope). The most prominent barriers to implementation of a model-based design were lack of suitable training, chief investigators’ preference for algorithm-based designs (e.g., 3+3), and limited resources for study design before funding
Conclusion
There is overwhelming evidence for the benefits of CRM. Many leading pharmaceutical companies routinely implement model-based designs. Our analysis identified barriers for academic statisticians and clinical academics in mirroring the progress industry has made in trial design. Unified support from funders, regulators, and journal editors could result in more accurate doses for later-phase testing, and increase the efficiency and success of clinical drug development. We give recommendations for increasing the uptake of model-based designs for dose-finding trials in academia.
Original languageEnglish
Publication statusPublished - 5 Nov 2017
EventNational Cancer Research Institute Cancer Conference - Liverpool, United Kingdom
Duration: 5 Nov 20178 Nov 2017
http://www.conference.ncri.org.uk

Conference

ConferenceNational Cancer Research Institute Cancer Conference
Abbreviated titleNCRI
Country/TerritoryUnited Kingdom
CityLiverpool
Period5/11/178/11/17
Internet address

Fingerprint

Dive into the research topics of 'Embracing model-based designs for dose-finding trials'. Together they form a unique fingerprint.

Cite this